Sanofi’s vaccines division -- Sanofi Pasteur -- has launched Shan5, its paediatric pentavalent vaccine developed and manufactured by its affiliate Shatha Biotechnic in India. The vaccine received prequalification status from Wold Health Organisation (WHO) in April 2014.
The launch of Shan 5 in India means that 27 million babies born annually in India will have access to vaccination to protect from five potentially deadly diseases. By launching the vaccine Shantha will be contributing to filling this immunisation gap for the benefit of babies and their parents.
The WHO prequalification helps Shantha secure the supply of pentavalent combination vaccines in over 50 emerging and low-income countries.
Sanofi, a global and diversified healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients’ needs. Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, rare diseases, consumer healthcare, emerging markets and animal health.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1797.80 |
Dr. Reddys Lab | 1213.90 |
Cipla | 1486.30 |
Lupin | 2069.95 |
Zydus Lifesciences | 948.70 |
View more.. |